Thelansis

Postmenopausal Osteoporosis Market Outlook Thelansis’s “Postmenopausal Osteoporosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Postmenopausal Osteoporosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the mar...

  Postmenopausal Osteoporosis Market Outlook Thelansis’s “Postmenopausal Osteoporosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Postmenopausal Osteoporosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Postmenopausal Osteoporosis Overview Postmenopausal osteoporosis is a condition that causes a progressive loss of bone tissue after natural or surgical menopause, leading to fractures within 15 to 20 years from the cessation of ovarian function. It is the most common form of primary osteoporosis. The drastic changes in estrogen and cytokine levels within the body are the main contributors to bone loss in postmenopausal os...

  Postmenopausal osteoporosis is a condition that causes a progressive loss of bone tissue after natural or surgical menopause, leading to fractures within 15 to 20 years from the cessation of ovarian function. It is the most common form of primary osteoporosis. The drastic changes in estrogen and cytokine levels within the body are the main contributors to bone loss in postmenopausal osteoporosis. Postmenopausal osteoporosis therapies are broadly classified into two categories: antiresorptive and osteogenic (bone anabolic). Antiresorptives slow down bone resorption and suppress bone turnover, while bone anabolics increase bone formation without affecting resorption, thus leaving bone turnover unaltered. Fractures severely affect the quality of life of an individual and are becoming a significant public health problem due to the aging population. Osteoporosis is diagnosed using bone density measurements of the lumbar spine and proximal femur. Hormone replacement therapy (HRT) is ...